Nashar Khaled, Nguyen Jacqueline P, Jesri Ammar, Morrow Jason D, Egan Brent M
Departments of Medicine and Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
Am J Hypertens. 2004 Jun;17(6):477-82. doi: 10.1016/j.amjhyper.2004.02.015.
Patients with the metabolic syndrome have three or more of five cardiovascular risk factors and increased oxidative stress, arterial stiffness and pressor responses to exercise, which may contribute to their threefold greater risk for coronary heart disease. In addition to lowering basal blood pressure (BP), angiotensin receptor blockers (ARBs) may benefit metabolic syndrome patients by reducing oxidative stress, arterial stiffness, and pressor responses to exercise. Twelve patients, 7 women and 5 men, with the metabolic syndrome (aged 45 +/- 2 years, BP 145 +/- 5/85 +/- 2 mm Hg, waist girth 110 +/- 3 cm, triglycerides 186 +/- 23 mg/dL, HDL cholesterol 44 +/- 2 mg/dL, glucose 99 +/- 3 mg/dL) were studied off medications, while on modest sodium restriction ( approximately 100 mmol/d). Patients were randomized to the ARB losartan or placebo for 3 weeks then crossed over to the complement for 3 weeks. Studies were performed at the end of each phase following an overnight fast. Serum lipids and biomarkers of oxidative stress (F2-isoprostanes, thiobarbituric acid reacting substances) were unchanged by losartan, whereas large artery elasticity at rest, measured with the HDI PulseWave, increased from 13.6 +/- 0.7 on placebo to 16.2 +/- 1.1 mL/mm Hg on losartan, P <.05. Losartan lowered systolic BP pre-exercise from 142 +/- 3 to 131 +/- 3 mm Hg (P <.001) and systolic BP after 6 min of treadmill exercise from 192 +/- 6 to 169 +/- 5 mm Hg (P <.001). Losartan lowered systolic BP (-23 +/- 3 v -11 +/- 2 mm Hg, P <.05) and pulse pressure (-4 +/- 1 v -15 +/- 2 mm Hg, P <.05) more during exercise than rest. Losartan reduces the pressor response to exercise, perhaps by enhancing arterial compliance. In addition to lowering basal BP, angiotensin receptor blockade in patients with metabolic syndrome improves arterial compliance and reduces pressor reactivity to exercise.
患有代谢综合征的患者具有五种心血管危险因素中的三种或更多种,并且氧化应激、动脉僵硬度和运动升压反应增加,这可能导致他们患冠心病的风险增加两倍。除了降低基础血压(BP)外,血管紧张素受体阻滞剂(ARB)还可能通过降低氧化应激、动脉僵硬度和运动升压反应而使代谢综合征患者受益。对12例代谢综合征患者(7例女性和5例男性,年龄45±2岁,血压145±5/85±2 mmHg,腰围110±3 cm,甘油三酯186±23 mg/dL,高密度脂蛋白胆固醇44±2 mg/dL,血糖99±3 mg/dL)在停用药物且适度限制钠摄入(约100 mmol/d)的情况下进行研究。患者被随机分为接受ARB氯沙坦或安慰剂治疗3周,然后交叉接受另一种治疗3周。在每个阶段结束时,经过一夜禁食后进行研究。氯沙坦对血脂和氧化应激生物标志物(F2-异前列腺素、硫代巴比妥酸反应物质)无影响,而使用HDI PulseWave测量的静息大动脉弹性,从安慰剂组的13.6±0.7 mL/mm Hg增加到氯沙坦组的16.2±1.1 mL/mm Hg,P<.05。氯沙坦使运动前收缩压从142±3 mmHg降至131±3 mmHg(P<.001),并使跑步机运动6分钟后的收缩压从192±6 mmHg降至169±5 mmHg(P<.001)。氯沙坦在运动期间比休息时更能降低收缩压(-23±3 vs -11±2 mmHg,P<.05)和脉压(-4±1 vs -15±2 mmHg,P<.05)。氯沙坦可能通过增强动脉顺应性来降低运动升压反应。除了降低基础血压外,对代谢综合征患者进行血管紧张素受体阻断可改善动脉顺应性并降低运动升压反应性。